Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

The grant supports building trial-based training and readiness programs for U.S. clinics ahead of COMP360’s potential approval and launch.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Strata’s implementation platform includes provider training, certification, site readiness, and ongoing clinical support; its founders worked with Compass on the COMP360 training program for clinicians, who supported and monitored participants in Compass' clinical trials.

ATLANTA--(BUSINESS WIRE)-- Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass’ investigational psilocybin treatment, if approved. Strata’s founders worked with Compass on the development of the provider training program for COMP360 clinical trials. Their team is deeply experienced in training clinicians and providing direct care to patients receiving psychedelic treatments in regulated clinical settings.

Compass has reported positive results from two Phase 3 trials of COMP360. Its NDA submission is expected to be complete in the fourth quarter of 2026 under a rolling submission and FDA review pathway, and commercial launch is expected in the first half of 2027. The training-partner grant program is intended to support the provider training of COMP360, if approved.

Psychedelic treatments are a novel approach to psychiatric care, where medication is delivered in multi-hour administration sessions under the care of trained, multidisciplinary teams, with additional sessions needed to prepare patients before and support them after receiving the medication. This is the treatment model that was used in clinical development. Strata is experienced to train the clinicians, prepare the clinics, and provide the ongoing support to translate the clinical trial model to real-world clinical practice to ensure responsible and effective dissemination of psychedelic treatment.

Under the grant, Strata will develop provider training programs for that delivery model. The work will be done by a team that contributed to the development of the COMP360 trial program. Strata plans to base its training program directly on the approach used in the trials, which will be taught by clinical faculty who have direct experience with the COMP360 clinical development program. Treatment teams in clinics will receive the same support as the teams in the trials, patients receive care that follows the standard set in the research.

“When we talk with clinics, they are excited about the potential for psychedelics to offer a new option for their patients. But they also want to know how to ensure treatment is delivered safely and responsibly,” said Mark Burton, PhD, Co-Founder and CEO of Strata. “Our answer is to start with the approach that was taken in the clinical trials and build from there. The standard of care does not need to drop when a treatment leaves the research setting. Making sure it doesn’t is our entire company.”

The grant-funded training is one component of Strata’s implementation platform. Multidisciplinary treatment teams will complete structured training and certification built from the program used in the COMP360 trials, taught through Strata’s learning platform and live practice with its clinical faculty.

Beyond training, Strata’s site-readiness consultation prepares the clinic itself, from workflows and screening to escalation pathways and quality assurance, built to exceed anticipated REMS requirements, and its support continues into early real-world delivery with case-based supervision and ongoing clinic support. Together, these give networks a system for onboarding psychedelic treatment programs and future treatments as they come to market.

“Our goal is to empower mental healthcare systems across the country to deliver high-quality psychedelic treatments to patients in need,” said Stephanie Knatz Peck, PhD, Co-Founder and Chief Clinical Officer. “We’re excited to build a program designed to equip providers with the core competencies to do this based on our deep experience in working with these compounds in clinical trial settings.”

Clinical networks preparing for regulated psychedelic treatments can begin with a readiness consultation with Strata’s clinical team. Learn more at www.stratamentalhealth.com.

About Strata Mental Health Solutions

Strata is the expert-led implementation partner preparing clinical networks to deliver psychedelic treatments. Its team developed and implemented the provider training program for COMP360, trained thousands of clinicians across psychedelic treatment models, and directly treated hundreds of patients across pivotal psychedelic clinical trials. Strata’s training, certification, and site-readiness programs connect with the systems clinics already use, so treatment teams can deliver new treatments safely from day one, at the standard set in the trials. Learn more at www.stratamentalhealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260911394726/en/

Media contact
info@stratamentalhealth.com

Source: Strata Mental Health Solutions

Key Terms

phase 3 medical

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

nda regulatory

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

rolling submission regulatory

A rolling submission is a regulatory filing process where a company sends portions of its application to health authorities as each section is completed, rather than waiting to submit the entire package at once. For investors, this can shorten the time to review and potential approval and reduces the risk of a single big setback—think of it like mailing chapters of a manuscript to an editor as they’re finished so feedback and progress happen sooner.

rems regulatory

Risk Evaluation and Mitigation Strategies (REMS) are safety programs required by regulators for certain medications to make sure their benefits outweigh known dangers; they can include extra training, special certifications for prescribers, restricted distribution channels, patient monitoring, or paperwork. For investors, REMS act like a safety checkpoint that can slow or limit a drug’s sales, raise costs, complicate manufacturing and distribution, and affect revenue forecasts and legal risk, so they matter for a product’s market potential and timeline.